Despite the advent of the genomic era, the perceived benefits of close collaboration between clinicians and scientists are not always realised and the gap between bench and bedside remains. Closer collaboration should expedite advances in treating disease. This important book, with a foreword by Fritz H Schroeder, is designed to enhance the relationship between the two communities. It contains data from a multinational authorship, the thirty-eight chapters being written by experts with widely differing training and expectations. Their aim is to facilitate both understanding and in-depth knowledge of their subject. By bridging the gap between clinicians and scientists, the hope is to enhance translational research in their common goal of improving the diagnosis and treatment of prostate cancer, the single most important cancer affecting men.
Prostate cancer - scientific and clinical aspects - bridging the gap: prostate cancer - the clinical dilemma; prostate cancer - the scientific dilemma. Epidemiology and genetics: epidemiology of prostate cancer; genetic aberrations in prostate tumours. Prostate gland - development differentiation and pathology (in relationship to malignancy): development and differentiation of the prostate gland; growth factors in prostatic development; the prostate and cancer - an introduction to normal morphology and histology for research scientists. Molecular and cell biology of prostate cancer: epithelial and mesenchymal cell lines of prostatic origin as models of prostate cancer; ion channels in prostate cancer; matrix metalloproteinases as potential targets for prostate cancer therapy; oncogenes and tumour suppressor genes in prostate cancer; emerging technologies and new strategies and prostate cancer research. New perspectives in prevention, control and clinical management of prostate cancer: prevention of prostate cancer; screening for prostate cancer; the molecular staging of prostate cancer; the care of patients with advanced hormone relapsed prostate cancer; the biology and treatment of bone metastases in prostate cancer; prostate cancer gene therapy; psychosocial support of the prostate cancer patient.